国际领先自愈合技术打破强生10年垄断 深企华诺生物产品获注册

Group 1 - The core achievement in the field of biomedical materials is the development of an absorbable hemostatic fluid gel by Shenzhen Huano Biotechnology Co., which has received the Class III medical device registration from the National Medical Products Administration (NMPA), breaking Johnson & Johnson's 10-year market monopoly in high-end hemostatic materials [1] - The product has already been implemented in nearly a thousand hospitals, with expectations to replace 30%-40% of Johnson & Johnson's market share by 2026, aiming for complete replacement within five years [1] - The breakthrough is attributed to 17 years of continuous research by Professor Wang Huanan's team, utilizing innovative "self-healing molecular technology" based on dynamic non-covalent bonding principles, allowing the material to quickly reorganize and restore its structure and strength after being damaged [1] Group 2 - Wang Huanan, a dual PhD holder in engineering and medicine, has a strong academic foundation that supports technological innovation, with over 100 papers published in top international journals and more than 30 patents granted [2] - Huano Biotechnology has a clear three-phase development plan focusing on surgical trauma repair, advancing to tissue regeneration medicine, and ultimately targeting organ repair and regeneration [2] - The company plans to develop 10 high-end Class III medical device products in the next five years, promoting the import substitution process of high-end medical consumables in China [2] Group 3 - Huano Biotechnology has established collaborations with several international institutions, with three innovative products, including injectable hydrogels and stem cell microcapsules, already approved for market [3]